Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.
      Google Scholar   
Citation:
J Gastrointest Cancer vol 38 (2-4) 87-94
Year:
2007
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
Parents:
551  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
CA-25224, CA-35103, CA-35113, CA-35119, CA-35267, CA-35269, CA-35448, CA-37404, CA-45450, CA-52352, CA-60276, CA35431  
Corr. Author:
 
Authors:
                 
Primary Study
NCCTG-N9943
Secondary Studies:
Phases:
1/2
Keywords:
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Deoxycytidine, Female, Gallbladder Neoplasms, Glutamates, Guanine, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Pemetrexed, Prognosis, Survival Rate, Treatment Outcome